RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.

Oncotarget · 2015 · PMC4694831 · PMID 26325371

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Besides, compared with vehicle, CDDP treatment reduced body weight of mice, while the RY-2f and combined treatment slightly reduced body weight, but did not reach statistical significance (Figure 6F ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.